Miniatura

Fitxers

adjuvant_dabrafenib_and_trametinib_for_patients.5.pdf (902.16 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-03-28

Llicència de publicació

cc by-nc-nd (c) Manzano, José L. et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/205363

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1097/CMR.0000000000000888

Resum

BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF-V600 mutations. However, real-world evidence is limited. We aimed to determine the feasibility of this therapy in routine clinical practice. DESCRIBE-AD, a retrospective observational study, collected real-world data from 25 hospitals in Spain. Histologically confirmed and resected BRAF-mutated melanoma patients aged & GE;18 years who were previously treated with dabrafenib plus trametinib adjuvant therapy, were included. The primary objectives were treatment discontinuation rate and time to discontinuation. The secondary objectives included safety and efficacy. From October 2020 to March 2021, 65 patients were included. Dabrafenib and trametinib discontinuation rate due to treatment-related adverse events (TRAEs) of any grade was 9%. Other reasons for discontinuation included patients' decisions (6%), physician decisions (6%), unrelated adverse events (3%), disease progression (5%), and others (5%). The median time to treatment discontinuation was 9 months [95% confidence interval (CI), 5-11]. G3-4 TRAEs occurred in 21.5% of patients, the most common being pyrexia (3%), asthenia (3%), and diarrhoea (3%). Unscheduled hospitalisations and clinical tests occurred in 6 and 22% of patients, respectively. After 20-month median follow-up (95% CI, 18-22), 9% of patients had exitus due to disease progression, with a 12-month relapse-free survival and overall survival rates of 95.3% and 100%, respectively. Dabrafenib and trametinib adjuvant therapy proved effective for melanoma patients in a real-world setting, with a manageable toxicity profile. Toxicity frequencies were low leading to low incidence of unscheduled medical visits, tests, and treatment discontinuations.

Matèries

Tractament adjuvant del càncer, Melanoma

Matèries (anglès)

Adjuvant treatment of cancer, Melanoma

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

MANZANO, José l., MARTIN LIBERAL, Juan, FERNÁNDEZ MORALES, Luis a., BENÍTEZ, Gretel, MEDINA MARTÍNEZ, Javier, QUINDÓS, María, GARCÍA CASTAÑO, Almudena, FERNÁNDEZ, Ovidio, SIMO, Rocío v., MAJEM, Margarita, BELLIDO, Lorena, AYALA DE MIGUEL, Pablo, CAMPOS BONILLA, Begoña, ESPINOSA, Enrique, MACÍAS CERROLAZA, José a., GIL ARNAIZ, Irene, LORENTE, David, RODRIGUEZ LESCURE, Alvaro, PEREZ, Victor n., LÓPEZ CASTRO, Rafael, GRAMAJE, María g., PUÉRTOLAS, Teresa, RODRIGUEZ MORENO, Juan f., ESPASA FONT, Laia, BELAUSTEGUI FERRÁNDEZ, Guillermo, CEREZUELA FUENTES, Pablo. Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study. _Melanoma Research_. 2023. Vol. 33, núm. 5, pàgs. 388-397. [consulta: 26 de gener de 2026]. ISSN: 0960-8931. [Disponible a: https://hdl.handle.net/2445/205363]

Exportar metadades

JSON - METS

Compartir registre